DIFFERENCES BETWEEN DEMOGRAPHICS OF GDS2019 SAMPLE WHO ANSWERED THE SPECIALIST SECTION ON THE USE OF PSYCHEDELICS IN PSYCHIATRY VS. OTHERS
• People who agreed to answer the GDS2019 specialist section on psychedelics had significantly higher rates of lifetime use of psychedelic drugs (80% vs. 57%) than those who only completed the initial screening questions. They also had higher rates (almost double) of both having past psychiatric history and being in receipt of current psychiatric medications than those who did not express interest in psychedelic therapies. • This means that although the analyses of the sample who completed the specialist section has an additional bias towards both psychedelics and considering psychedelics as a therapeutic option, the results are perhaps even more important given that 43% had previously been given a psychiatric diagnosis and almost one in five were currently receiving some type of psychiatric medication. These are the very groups who will be most relevant when exploring the acceptability of novel psychiatric treatments. • In the following slides we offer preliminary analyses of this sample.
Global Drug Survey GDS2019 © Not to be reproduced without authors permission